GUSTO III trial comparing Boehringer Mannheim's reteplase to Activase to begin in summer 1995.
Executive Summary
GUSTO III COMPARING RETEPLASE WITH ALTEPLASE TO BEGIN IN SUMMER OF 1995 enrolling 10,000 to 12,000 patients experiencing myocardial infarctions, Boehringer Mannheim reported March 20. The announcement by the manufacturer of reteplase, a novel modified recombinant plasminogen activator, came during the annual meeting of the American College of Cardiology in New Orleans.